TTR vs. AL cardiac amyloidosis: Don't rely on imaging alone July 02, 2019 Overview Show transcript Overview Mayo Clinic cardiologists Martha Grogan, M.D., and Omar F. Abou Ezzeddine, M.D., C.M., M.S., discuss transthyretin (TTR) amyloidosis and AL amyloidosis. General characteristics of cardiac amyloidosis can include unexplained heart failure, unexplained atrial fibrillation, and physical exam findings such as jugular venous pressure elevation, lower extremity edema, and abdominal distension. Diagnosis and treatment of amyloidosis vary depending on the type. Patients with amyloidosis can deteriorate rapidly, so diagnosing quickly is very important. This video first appeared on theheart.org | Medscape Cardiology. | Share Doximity Facebook LinkedIn Twitter Print details Email Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleNew ATTR amyloidosis treatmentVideoGrand Rounds: Cardiac Amyloidosis: What Every Cardiologist Needs to KnowVideoCardiac Amyloidosis — The Great Imitator VID-20464757 Medical Professionals TTR vs. AL cardiac amyloidosis: Don't rely on imaging alone